Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples